Revolutionizing Navidea Biopharmaceuticals: Dana J Moss, JD Joins the Board of Directors

Navidea Biopharmaceuticals, Inc. has recently announced the addition of Dana J Moss, JD to their Board of Directors. With a wealth of legal experience and expertise in life sciences and technology, Moss's appointment will undoubtedly contribute to Navidea's mission of developing precision immunodiagnostic agents and immunotherapeutics. In a separate development, Amit Bhalla has decided to step down from the Board.

Dana J Moss brings years of leadership and legal expertise in innovative organizations focused on life sciences and technology-driven products. Her career in both private and public entities provides a valuable perspective to guide Navidea's business strategy, manage risks, and deliver value to shareholders. Dr. Jason Myers, Owner and Founder of G2G Ventures, expressed his confidence in Moss's capabilities, stating, "Dana understands where we are and where we are heading, and has the skills and experience to guide Navidea's technology and assets to the forefront."

Previously, Moss served as the Chief Legal Officer and Corporate Secretary at Sequencing Health, Inc., where she was responsible for legal, regulatory, compliance, and intellectual property matters. She also led fundraising and merger and acquisition strategies while overseeing finance, corporate governance, and human resources functions. Her experience includes serving as General Counsel, Corporate Secretary at Genapsys, Inc., as a Partner at Cooley LLP specializing in Commercial Litigation, and as a Program Manager at Mantech International Corporation. Moss's background also includes serving as a Special Agent and Operations Officer of the U.S. Air Force Office of Special Investigations. She holds a Bachelor of Science degree from the United Air Force Academy, where she graduated as a distinguished graduate. She also earned a Master of Arts in Philosophy from the University of Texas at Austin and a Juris Doctorate from the University of Maryland Francis King Carey School of Law, graduating cum laude.

In addition to her professional accomplishments, Moss is recognized as a 2021 Fellow of the Leadership Council on Legal Diversity and has served on the organizing Board of MissionLink, a nonprofit membership organization for C-level executives of high-growth technology companies.

While Navidea welcomes Dana J Moss, JD, the company bids farewell to Amit Bhalla, who has decided to step down from the Board to pursue other business interests. Bhalla's strategic guidance and expertise in the emerging medical technology space have been vital in driving Navidea's business forward. The company expresses its gratitude for Bhalla's contributions and wishes him the very best in his future endeavors.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company at the forefront of developing precision immunodiagnostic agents and immunotherapeutics. Their focus on precision targeting through the Manocept platform aims to enhance patient care, improve diagnostic accuracy, inform clinical decision-making, and enable targeted treatment. The Manocept platform is built on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. Tc99m tilmanocept, the first product developed and commercialized by Navidea based on this platform, is just one of the many precision-targeted products in the company's development pipeline. Navidea strives to deliver superior growth and shareholder returns by bringing novel products to market and forging global partnerships for commercialization.

Navidea's partnership with G2G Ventures, a Colorado-based private equity firm, further strengthens their mission. G2G Ventures empowers organizations to reach their full potential through investment and consulting services. By providing capital solutions, such as private equity investment, venture capital participation, and mezzanine debt options, G2G Ventures fosters long-term partnerships and actively supports businesses in achieving strategic goals and operational effectiveness.

In conclusion, Navidea Biopharmaceuticals, Inc. welcomes Dana J Moss, JD, to their Board of Directors, reinforcing their legal and strategic expertise in the field of life sciences and technology. With Moss's addition, Navidea is well-positioned to continue advancing innovative technologies and assets, ultimately revolutionizing precision immunodiagnostic agents and immunotherapeutics. As the company continues to develop its pipeline and pursue global partnerships, it remains committed to delivering superior growth and shareholder value.